Report Overview

The EU Osteoarthritis Therapeutics Market is estimated at $6.8 billion in 2019 and projected to reach XXbillion by 2024 at a CAGR of XX% during the forecast period

The EU osteoarthritis therapeutics market has seen consistent growth in recent years, driven by the high cost of biologics, unmet needs in the RA space, and the efficacy of ant-TNF biologics. Drug manufacturers are expected to experience significant losses of market share due to the entry of lower-priced biosimilars that will experience rapid growth due to their affordability. Osteoarthritis is the most common form of arthritis that causes pain, swelling, and reduced motion in the joints. Usually, osteoarthritis affected joints are inclusive of hands, knees, hips, and spine. Osteoarthritis breaks the cartilage of the joints which is a slippery tissue covering the ends of bones in a joint



Market Growth Drivers

EU accounted for the largest market share in 2019. The rising cases of osteoarthritis, increasing geriatric, and obese populations in the region are the major factors driving the growth of this market in the EU. The adoption of pain medications for the management of pain associated with osteoarthritis is expected to remain high over the coming decade, which is anticipated to propel the growth of the market during the study period